Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAdministrative/Operational PolicyHumana Prior Auth & Notification List | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHumanaPolicy N/A

    Humana Dual Integrated South Carolina prior authorization and notification list

    Customize your policy alerts

    Sign up for all Humana policy alerts

    Know when Humana releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization and notification requirements for medications (professionally administered/in-office, outpatient, home) and related services for Humana Dual Integrated (HMO D-SNP) members in South Carolina; affects participating providers, facilities, and delegated networks.

    Policy Summary
    PayerHumana
    PolicyHumana Dual Integrated South Carolina prior authorization and notification list
    Policy CodePolicy N/A
    Change TypeMinor / no material coverage changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionInitiate prior authorization requests via CoverMyMeds online, phone 866-461-7273 (TTY:711) Mon–Fri 8a–11p ET, or fax 888-447-3430.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3ways to initiate prior authorization
    90 daystemporary PA waiver (new members)
    866-461-7273PA phone
    888-447-3430PA fax
    National Transplant Networktransplant reviewer

    Coverage and Product Listings

    High-level coverage criteria and procedures

    Covered when ALL of the following administrative and program requirements are met:

    Medications and services must meet Medicare/CMS coverage guidelines and be medically necessary as defined by CMS

    See CMS coverage guidelines and Humana Medical and Pharmacy Coverage Policies for details.

    Medications delivered in a provider office, clinic, outpatient or home setting listed on this document require prior authorization before administration

    Prior authorization is defined as advance approval from the plan that an item or service will be covered.

    Investigational or experimental procedures/devices are generally not covered; consult the member's Evidence of Coverage or Humana to confirm coverage
    Advance coverage determination (ACD) is available for investigational/limited benefit services and certain medication requests

    ACD requests can be initiated via the usual PA submission methods (phone, fax, CoverMyMeds).

    Policy Summary
    PayerHumana
    PolicyHumana Dual Integrated South Carolina prior authorization and notification list
    Policy CodePolicy N/A
    Change TypeMinor / no material coverage changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionInitiate prior authorization requests via CoverMyMeds online, phone 866-461-7273 (TTY:711) Mon–Fri 8a–11p ET, or fax 888-447-3430.
    SourceLink
    On This Page
    Coverage and Product ListingsBilling Codes and MappingsHow to Request Authorization and Provider ResponsibilitiesFlags and Term Definitions
    Step therapy requirements may apply to Medicare Part B medications; review Humana's Part B Step Therapy Preferred Drug List for specific criteria and cross-benefit strategies
    All shared HCPCS codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on claims where indicated (marked '‡')
    Urgent or emergent services do not require prior authorization
    Providers should include required administrative information when submitting an authorization request, including up to 6 diagnosis codes per request

    Drug/Code listings and PA/notification flags (partial)

    Medication entries list brand name, generic name, and associated billing codes; annotations signal special processing requirements:

    Each listed drug entry includes: 1 = generic medication name; 2 = billing codes (HCPCS/J-, Q-, or A- codes)
    Entries may be annotated with special flags: '*' = new preauthorization requirement; '†' = new-to-market drug addition; '‡' = shared HCPCS/NOC code requiring an NDC on claims; '**' = step therapy required; '††' = routed to Humana National Transplant Network for review
    Where an entry is marked with '‡', providers must include the corresponding NDC on claims for billing accuracy

    Listing format and annotations

    Listing format and annotation conventions used throughout the product list:

    Format for each listing: Brand name, optional flag(s), therapeutic category; 1 = generic medication name; 2 = billing code(s)
    Flag conventions: '*' = new preauthorization requirement; '†' = new-to-market addition; '‡' = shared HCPCS/NOC code requiring an NDC; '**' = step therapy required through Humana-preferred drug; '††' = transplant review routing to Humana National Transplant Network
    The presence of '**' indicates a step therapy requirement that must be met as part of prior authorization review

    Prior authorization — product list (no clinical criteria in these chunks)

    The following products (examples shown) require prior authorization; HCPCS billing codes accompany each listing. Flags shown in the list indicate additional billing or review requirements.

    Examples (blood‑clotting factors)

    • Advate — antihemophilic factor, human recombinant — J7192
    • Adynovate — antihemophilic factor (recombinant), PEGylated — J7207
    • Afstyla — antihemophilic factor (recombinant) single chain — J7210
    • Hemlibra ** — emicizumab-kxwh — J7170 (marked '**' indicates step therapy)
    • Kogenate FS ‡ — antihemophilic factor (recombinant) — J7192 (marked '‡' requires NDC on claims)

    Billing Codes and Mappings

    Sample medication billing codes (partial list)HCPCS
    Q2055Abecma intravenous suspension
    J9264Abraxane (paclitaxel-nab)
    J3262Actemra IV (tocilizumab)
    Additional medication billing codes (partial)HCPCS
    J9035Avastin (bevacizumab) — auth only for oncology/chemo use
    J3145Aveed (testosterone undecanoate)
    Q5121Avsola (infliximab biosimilar)
    Example drug-to-billing-code mappings (partial list)HCPCS
    J0178Aflibercept (Eylea)
    J1428Eteplirsen (Exondys 51)
    J3111Romosozumab-aqqg (Evenity)
    Examples of J-codes present in listHCPCS
    J9316Phesgo (trastuzumab and hyaluronidase-zzxf) billing code
    J1745Remicade (infliximab) billing code
    J0897Prolia / Xgeva (denosumab) billing code
    Listed HCPCS J-codes for blood-clotting factorsHCPCS
    J7192Used for several antihemophilic factor products (examples: Advate, Kogenate FS, Recombinate)
    J7207Adynovate (antihemophilic factor [recombinant], PEGylated)
    J7210Afstyla (antihemophilic factor [recombinant] single chain)
    J7173Alhemo (concizumab-mtci)
    J7186Alphanate (antihemophilic factor/von Willebrand factor complex [human])
    J7193AlphaNine SD (coagulation factor IX [human])
    J7201Alprolix (coagulation factor IX [recombinant])
    J7214Altuviiio (efanesoctocog alfa)
    J1414Beqvez (fidanacogene elaparvovec-dzkt)
    J7175Coagadex (coagulation factor X [human])
    1–10 of 37
    1/4
    Coding threshold
    Maximum diagnosis codes per authorization request6
    Information required (diagnosis codes)Include primary and secondary diagnosis codes up to the maximum per request
    PurposeUsed for prior authorization determination and claim processing

    How to Request Authorization and Provider Responsibilities

    Prior Authorization

    Prior Authorization Required

    Humana requires prior authorization for certain medications and services listed in this document. Prior authorization (also called preauthorization or precertification) is the process by which the provider must obtain advance approval from Humana to determine whether an item or service will be covered. Services provided without required prior authorization may be subject to retrospective medical necessity review and potential denial or financial penalties. Providers should submit all relevant clinical information with the request to expedite determination.

    • Prior authorization applies to medications administered in-office, outpatient, or home settings.
    • Failure to obtain required prior authorization may result in claim denials or reduced payment and retrospective review.
    Note

    How to Request Prior Authorization / ACD

    To request prior authorization or an advance coverage determination (ACD) for medications, providers may use one of the following methods unless otherwise noted for specific drugs:

    • Online: CoverMyMeds (http://www.covermymeds.com/)
    • Phone: 866-461-7273 (TTY: 711), Monday - Friday, 8 a.m. - 11 p.m., Eastern time
    • Fax: 888-447-3430 (request forms available on Humana's prior authorization for professionally administered drugs website)
    • ACDs for medications may also be initiated by phone at 866-461-7273 or fax to 888-447-3430. Include all relevant clinical information to prevent delays.
    Note

    Urgent Care and Delegated Network Note

    Urgent or emergent services do not require prior authorization. Providers participating in delegated risk networks or independent practice associations (IPAs) should follow their IPA or network guidance for authorization processing; however, the full prior authorization requirements still apply and may be enforced by Humana. If services are delegated, verify whether the IPA or delegated entity will handle the request or if submission to Humana is required.

    • Urgent/emergent services: no prior authorization required.
    • Delegated network/IPA providers: follow the IPA/network process and confirm routing for PA requests.
    Step Therapy

    Step Therapy Guidance

    Humana's step therapy program applies to certain Medicare Part B medications and may require trial of a Humana-preferred drug before approval of the requested medication. Providers should consult Humana's Medicare Part B Step Therapy Preferred Drug List (PDL) for preferred and nonpreferred medications, including cross-benefit strategies that may span Part B and Part D. The preferred status does not guarantee exemption from step therapy; review specific coverage criteria and step therapy indicators on the Medicare PAL.

    • Step therapy indicators are noted on the Medicare prior authorization list.
    • If a provider does not stock a preferred medication, a pharmacy may supply it (see Humana's specialty and mail-order pharmacy listings).
    • Step therapy may require cross-benefit trials (Part B vs Part D) — see the Part B Step Therapy PDL for details.
    Note

    Transplant Preauthorization Routing

    Certain preauthorization requests for transplant-related services and therapies will be routed to the Humana National Transplant Network for review. Providers should submit these transplant preauthorization requests using the transplant-specific contact methods.

    • Transplant preauthorization routing: requests reviewed by Humana National Transplant Network.
    • Transplant submission contacts: fax 502-508-9300; phone 866-421-5663 (Mon–Fri, 7 a.m.–7 p.m. Central); email transplant@humana.com.
    Billing Rule

    Prior Authorization Qualifiers and Billing Requirements

    Prior authorization qualifiers and billing requirements: Humana may add new preauthorization requirements or step therapy requirements throughout the year. All shared HCPCS and not otherwise classified (NOC/C9399/J3490/J3590) codes billed for medications require a corresponding National Drug Code (NDC) on the claim. Providers must ensure claims include the correct NDC when using shared HCPCS/NOC codes to avoid claim denials.

    • New preauthorization requirements and step therapy additions may be implemented during the year — check Humana's provider prior authorization notification lists website for updates.
    • All shared HCPCS and NOC codes (including C9399, J3490, J3590) require the corresponding NDC on the claim.
    • Failure to include the NDC for shared HCPCS/NOC codes may result in claim payment issues or denials.

    Flags and Term Definitions

    Prior authorization (definition)
    DefinitionPrior authorization is a process through which the healthcare provider is required to obtain advance approval from the plan as to whether an item or service will be covered.
    Applies toMedications delivered in provider office, clinic, outpatient or home settings listed on the document
    Related guidanceServices must follow Medicare/CMS coverage guidelines and Humana coverage policies
    Part B Step Therapy PDL (definition)
    NamePart B Step Therapy Preferred Drug List (PDL)
    PurposeDesignates preferred and nonpreferred medications and describes cross-benefit step therapy strategies for Medicare Part B medications
    Action for providersReview Humana's Part B Step Therapy PDL alongside Humana coverage policies when step therapy indicators appear on the Medicare PAL
    HCPCS / NOC NDC billing requirement (‡)
    Symbol‡
    MeaningAll shared HCPCS codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims
    Provider actionEnsure the corresponding NDC is included on claims for items marked with ‡
    Step therapy flag (**)
    Symbol**
    MeaningStep therapy required through a Humana-preferred drug as part of preauthorization
    Provider actionConfirm whether a trial of a preferred medication is required per Humana's Part B Step Therapy PDL when ** is present
    Transplant review flag (††)
    Symbol††
    MeaningPreauthorization requests for items marked with †† will be reviewed by the Humana National Transplant Network
    Submission methodsTransplant reviews can be submitted by fax to 502-508-9300, phone 866-421-5663 (M–F 7 a.m.–7 p.m. CT), or email transplant@humana.com
    New preauthorization / new-to-market markers (*, †)
    Symbols* and †
    Meaning'*' indicates a new preauthorization requirement; '†' indicates a new-to-market drug addition
    Provider actionNote change markers on the listing to identify newly added preauthorization requirements or new-to-market products
    ‡ (NDC billing requirement)
    Symbol‡
    Meaning (explicit)'‡' indicates shared HCPCS or not otherwise classified codes that require a corresponding NDC on claims
    Repeated noteMultiple chunks reiterate that shared HCPCS/NOC codes marked with ‡ must include an NDC on all claims
    ** (step therapy)
    Symbol**
    MeaningIndicates step therapy is required through a Humana-preferred drug as part of preauthorization
    Provider actionRefer to Humana's Part B Step Therapy PDL for trial and preferred-drug details when ** appears
    ‡ (billing note duplicate)
    Symbol‡
    MeaningIndicates shared HCPCS codes and NOC codes require an NDC on all claims
    InstructionEnsure NDC presence on claim submissions for items marked with ‡ to avoid claim processing issues
    ** (step therapy duplicate)
    Symbol**
    MeaningDenotes step therapy requirement through a Humana-preferred drug as part of preauthorization
    ActionFollow Part B Step Therapy PDL and document trials of preferred medications where required
    * / † (change markers)
    Symbols* and †
    Definitions'*' = new preauthorization requirement; '†' = new-to-market drug addition
    Provider implicationWatch listings for these markers to identify policy changes affecting authorization needs
    †† (transplant review note duplicate)
    Symbol††
    MeaningIndicates preauthorization requests will be reviewed by the Humana National Transplant Network with provided contact methods
    Contact detailsFax 502-508-9300; phone 866-421-5663 (M–F 7 a.m.–7 p.m. CT); email transplant@humana.com